Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Timothy Howard

Family Medicine Huntsville, AL Medical Doctor

NPI 1619964343 CMS profile 163747

1102 Gleneagles Dr Sw, Huntsville, AL 35801

Open in the dashboard

General payments

$664

18 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,030,993 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Timothy Howard of Huntsville, AL is reported in the CMS Open Payments database as having received $664 across 18 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $3,030,993 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 63rd percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $76 2
2024 General $203 1
2023 General $74 2
2022 General $50 3
2021 General $74 5
2020 General $33 2
2019 General $154 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Howard
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Timothy Howard were reported at $76. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Timothy Howard Family Medicine median Middle half National median
2019 $154 $150 $41–$543 $163
2020 $33 $120 $32–$415 $114
2021 $74 $137 $35–$551 $132
2022 $50 $137 $37–$512 $149
2023 $74 $149 $42–$545 $160
2024 $203 $156 $44–$560 $164
2025 $76 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $203 1 payment
  2. Boehringer Ingelheim Pharmaceuticals, Inc. $122 1 payment
  3. Solta Medical, a division of Bausch Health US, LLC $70 1 payment
  4. Abiomed $60 1 payment
  5. AbbVie, Inc. $54 3 payments
  6. Organogenesis Inc. $30 2 payments
  7. KCI USA, Inc $19 1 payment
  8. Genentech USA, Inc. $17 1 payment
  9. ConvaTec Inc. $17 1 payment
  10. Amarin Pharma Inc. $15 1 payment
  11. Other $57 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $461 17 payments
  2. Travel and Lodging $203 1 payment
Products named General payments · program years 2019–2025
  1. PROPHECY $203 1 payment
  2. JARDIANCE $122 1 payment
  3. Impella $60 1 payment
  4. DALVANCE $54 3 payments
  5. Puraply $30 2 payments
  6. Xofluza $17 1 payment
  7. Esteem + $17 1 payment
  8. Vascepa $15 1 payment
  9. INSPIRE $14 1 payment
  10. OASIS $13 1 payment
  11. Other $43 4 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 22 billing codes

Paid by Medicare

$12,576

Of which drugs: $2,049

Medicare patients

215

Average age 77

Services billed

588

126 women, 89 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Ischemic heart disease 36%
Diabetes 33%
Chronic kidney disease 31%
Depression 22%
Atrial fibrillation 20%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 66 68 $1,046
Pcv20 vaccine im 90677 Office 11 11 $584
Vaccine for tetanus, diphtheria toxoids and acellular pertussis (whooping cough) for injection into muscle, patient 7 years or older 90715 Office 21 24 $240
Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 Office 43 43 $88
Vaccine for influenza for injection into muscle 90653 Office 23 23 $82
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 12 36 $9
Vaccine for influenza for injection into muscle 90662 Office 14 14 $0

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

18 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record